Identification of a BCR polymorphism in a bone marrow donor: diagnostic implications

TO THE EDITOR
The Philadelphia chromosome (Ph 1 ) is a characteristic cytogenetic feature of chronic myelogenous leukemia (CML), involving reciprocal translocation of the ABL proto-oncogene on chromosome 9 to the breakpoint cluster region (BCR) of chromosome 22. The gene rearrangement may be detected by a number of different molecular diagnostic methods, such as genomic Southern hybridization (GSH) for a non-germline BCR pattern or RT-PCR for the presence of a BCR/ABL fusion transcript.
For patients with CML, high-dose chemotherapy followed by allogeneic bone marrow transplant (BMT) is the preferred treatment when a histocompatible donor is available. Such patients are subsequently monitored for the presence of a BCR gene rearrangement, detection of which is predictive of relapse. Interpretation of test results obtained by RT-PCR is straightforward. A positive result is marked by the presence of a sequence-specific BCR/ABL product and a negative result shows the absence of such a product, when the RNA integrity has been confirmed with a standard PCR primer set. GSH interpretation is more complex and requires, for a sample to be considered positive for a BCR rearrangement, that it either demonstrate a non-germline hybridization pattern with more than one enzyme or that a single positive enzyme generate bands of unequal intensity. This latter assay, although potentially more problematic, provides semi-quantitative data not obtainable by RT-PCR analysis, and this information may prove useful in following patients being treated on a clinical trials protocol.
We report here the diagnostic implications of such a case in which a BMT patient exhibited an apparent BCR gene rearrangement following transplant. The altered band pattern was in fact the result of a previously reported tutional polymorphism in the donor DNA, identified by GSH in the setting of mixed chimerism.
A 27-year-old black male was diagnosed with CML in chronic phase, with the karyotype 46,XY,t(9;22)(q34;q11) [20] , and received an allogeneic BMT from his HLA-matched 26-year-old sister. The preparative regimen for transplantation included cyclophosphamide 50 mg/kg for 4 days and total body irradiation 300 cGy/day for 4 days. Prior to transplant, the patient-donor pair was found to be informative with a locus-specific hypervariable DNA probe, MS-1 (9), which subsequently was utilized to monitor the success of bone marrow engraftment. The patient's DNA sample at this time was negative by GSH for a BCR gene rearrangement using a 600 bp probe for the 5Ј region of the BCR gene, presumably because pre-BMT therapy reduced the disease burden below the 5% detection limit of the Southern blot, and no RT-PCR assay for BCR/ABL was requested or performed. Cyclosporine was given as prophylaxis for graft-versus-host disease beginning 2 days prior to marrow infusion and was continued throughout the patient's course. There was no evidence of graft-versushost disease. During the first 150 days after transplantation, the clinical impression was one of poor engraftment of unclear etiology; total WBC at 30, 90, 120, and 150 days was 215, 500, 1400 and 1600/mm 3 , respectively, with the patient receiving frequent red blood cell and platelet transfusions. G-CSF was given beginning on day 100 and continued until WBC improved. No further red cell or platelet transfusions were required after 6 months.
After BMT the patient was followed at regular intervals by molecular diagnostics for engraftment and/or BCR gene rearrangement. Bone marrow specimens assayed with the MS-1 probe at 30 and 90 days showed evidence of mixed chimerism of 40-45% and 45-50% host, respectively (Figure 1 ). At 30 days post-BMT there was no indication by RT-PCR of a BCR/ABL transcription product using a published method 3 with PCR primers for the BCR exons b2/b3 and e1, and ABL exon a2. Due to suboptimal sample quantity and/or quality, no additional BCR data could be obtained at these time- points. At 120 days post-BMT BCR analysis was performed on a peripheral blood specimen and the RT-PCR assay was negative for a BCR/ABL fusion transcript. However, by GSH there was a clear BCR gene rearrangement detected with one of three restriction enzymes (BamHI), at a level corresponding to 40-45% of the DNA (and correlating to 80-90% of the cells) in the sample (Figure 2a) . Additional testing showed this rearrangement, absent from the patient's pre-BMT bone marrow specimen, to be present in donor DNA at the 50% level associated with allelic polymorphism (Figure 2b) . No MS-1 assay was requested on the 120-day sample at the time of collection and there was insufficient material to perform the test retrospectively. However, DNA extracted from additional BM samples obtained from the patient at 150 days and 8 months post-BMT demonstrated only the donor's hybridization pattern, with no evidence of mixed chimerism. The WBC was 3100 at 8 months and the patient was clinically well.
The interpretation of molecular genetic assays in the diagnosis of cancer can greatly influence the course of treatment and prognosis for the patient involved. However, there are difficulties inherent in the use of molecular technology to diagnose somatic cell changes, where the results are rarely as clear-cut as in constitutional genetic analysis. While normal nucleotide variation in the general population is critical for routine linkage studies, polymorphisms in tumor marker loci create the potential for misinterpretation. This case illustrates one such situation, in which a post-BMT patient harbored an apparent BCR gene rearrangement by GSH.
There were several unusual findings in this case which provided clues to the nature of the false-positive BCR result. First, the specimen which had an apparent rearrangement by GSH was negative for a BCR/ABL fusion transcript by RT-PCR. This result alone is not conclusive as several CML patients have been reported with atypical ABL exon 3 (a3) breakpoint junctions 4-6 not detectable with our RT-PCR assay, but these variants occur only very rarely. 4 Second, the BCR rearrangement was identified with only one restriction endonuclease, BamHI, and although it represented less than the 50% of the DNA expected of a polymorphism, the band pattern was consistent with a previously reported allele polymorphism found in an estimated 2% of the population. 2 Third, the rearranged pattern was identified in a patient with a recent history of mixed chimerism for bone marrow engraftment.
The last point allowed definitive analysis of the patient specimen and provided an explanation of the GSH findings. The patient's pre-transplant bone marrow did not exhibit the altered BCR band. The healthy donor was not examined before transplant for a BCR gene rearrangement, in accordance with our clinical laboratory practice of providing costeffective testing. However, when assayed retrospectively for a BCR rearrangement, the donor exhibited the additional BamHI band pattern at the 50% level consistent with a constitutional polymorphism. Additionally, although it was not possible to determine the level of mixed chimerism present in the patient's bone marrow specimen obtained 120 days post-BMT, at 90 days there was 40-45% host (55-60% donor) present and the sample at 150 days was all donor. By extrapolation, the specimen at 120 days would have been approximately 80-90% donor. Since the donor had one normal and one polymorphic BCR allele, this level of mixed chimerism would account for the 40-45% apparent BCR rearrangement seen in the 120-day post-BMT sample. Thus, the results obtained for the BCR tumor marker combined with the presence of mixed chimerism are consistent with the absence of a BCR gene rearrangement in the patient's post-BMT specimen.
Although in this instance an alternative assay was available to provide a clear diagnosis and the BCR BamHI polymorphism had been previously reported, this is not true of all clinically relevant tumor markers. For example, MLL (11q23) rearrangements in acute leukemia can involve reciprocal translocations with at least 25 other chromosome regions 7 and Southern blot detection is often employed since a PCR-based assay might easily miss a gene rearrangement. Also, MLL polymorphisms have not been described. In conclusion, this novel case serves as an example of the possibility of misinterpreting Early detection of AML1/MTG8 fusion mRNA by RT-PCR in the bone marrow cells from a patient with isolated granulocytic sarcoma TO THE EDITOR Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature granulocytes. GS usually develops as a precursor to blastic crisis in myeloproliferative and myelodysplastic syndromes or during the course of acute myelogenous leukemia (AML).
1,2 It is rarely recognized as an isolated tumor without any evidence of leukemia. In such cases, however, leukemia generally develops within a matter of months from the diagnosis of GS. 2 A close relationship between GS and gene abnormality was first reported by Swirsky et al; 3 subsequently, several karyotype abnormalities were demonstrated in GS patients. 4 In this report, we first demonstrated a chimeric gene transcript in the bone marrow cells in a patient with isolated GS. This case will help in understanding prognosis of such a patient.
A 22-year-old female was hospitalized in May 1996, due to numbness of her left foot for 3 months. Systemic computed tomography showed a giant intrapelvic mass (18 × 11 × 9 cm) with hydronephrosis of the left kidney due to obstruction of the left ureter by the tumor (Figure 1 ). Ga scintigraphy was positive at the tumor, but no other lesions were detected. Several examinations including peripheral blood count, bone marrow film, cerebrospinal fluid and karyotype analysis were normal. She was tentatively diagnosed as rhabdomyosarcoma, then, open biopsy was performed for differential diagnosis by using a standard panel of immunohistochemical antibodies. 5 Immunohistochemical features of the obtained specimen were as follows: DF-T1 (CD43), ++; LCA(CD45), ++/+; myeloperoxidase, ++; naphthol-ASD-chloroacetate esterase, +; LeuM1(CD15), −; UCHL-
